
|Articles|June 1, 2003
Moxifloxacin gains FDA approval
Author(s)Lynda Charters
Dallas-Moxifloxacin ophthalmic solution (Vigamox 0.5%, Alcon Laboratories) was approved by the FDA on April 16 for the treatment of bacterial conjunctivitis, following a 6-month review of the drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
2
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
3
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease
4
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
5












































.png)


